TROG 94.01/AGITG IG9401 - Oesophagus - Localised Resectable (IG9401)

TROG 19.06 DECREASE trial marks recruitment milestone

Read our latest Annual Report highlighting TROG achievements

By w.paterson
15 August, 2021
0 Comments

A Randomised Phase III Clinical Trial Comparing Surgery Alone with Concurrent Preoperative Chemotherapy and Radiation Followed by Surgery For Localised Resectable Carcinoma of the Oesophagus

Primary Sponsor

Trans-Tasman Radiation Oncology Group (TROG)

Collaborating Groups

Australasian Gastro-Intestinal Cancer Trials Group (AGITG)

24 July, 2025

Five questions about the inaugural World Radiotherapy Awareness Day: 7 September

LATEST NEWS: 24 July 2025 The inaugural World Radiotherapy

15 July, 2025

New paper outlines protocol for important TROG 20.01 CHEST-RT lung cancer trial

TRIAL UPDATE: 15 July 2025 The TROG 20.01 CHEST-RT

For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.

Quick Links

Legalities

A Randomised Phase III Clinical Trial Comparing Surgery Alone with Concurrent Preoperative Chemotherapy and Radiation Followed by Surgery For Localised Resectable Carcinoma of the Oesophagus

TROG 95.01 – Rectal Cancer

TROG 92.01 – PCNSL (Phase II)

Related Post

Five questions about the inaugural World Radiotherapy Awareness Day: 7 September

New paper outlines protocol for important TROG 20.01 CHEST-RT lung cancer trial